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Abstract
Volatile anesthetics are one class of the most commonly used drugs. However, the mechanisms for these drugs to
induce anesthesia are not fully understood and have been under intensive investigation. Two other effects of these
anesthetics on the central nervous system, volatile anesthetics-induced neuroprotection and neurotoxicity, currently
are hot research fields. Although data from animal studies for these two effects are extensive and convincing,
clinical data for volatile anesthetics-induced neuroprotection are relatively weak. There is essentially lack of
evidence to suggest volatile anesthetics-induced neurotoxicity in humans. In this regard, the contribution of
general anesthesia/anesthetics to postoperative cognitive decline, a clinical entity whose existence has been
supported by substantial evidence, also has not been established. This paper will be focused on reviewing the
evidence, especially the clinical evidence, for volatile anesthetics-induced neuroprotection and neurotoxicity. Efforts
will be devoted to facilitating the understanding of the two seemingly contradictory effects of these important
drugs on the brain.
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Introduction
More than 20 millions of patients each year have sur-
geries in the USA. The majority of these surgeries are
performed under general anesthesia. About 80% of them
receive volatile anesthetics as their primary anesthetics
[1]. Since the first use of ether, a volatile anesthetic, in
1842, volatile anesthetics have be the major class of gen-
eral anesthetics used in the clinical practice for near 160
years.
Although it is still controversial among the experts, it
is generally accepted that general anesthesia minimally
includes the following components: unconsciousness,
insensateness, analgesia and amnesia. Many experts will
also add muscle relaxation and bluntness of cardiovas-
cular response to surgical stimulation into the compo-
nents of general anesthesia. Volatile anesthetics, unlike
most intravenous anesthetics, have pharmacological
properties to provide all components of general anesthe-
sia [2]. Thus, volatile anesthetics are full general anes-
thetics and, theoretically, single volatile anesthetic can
be used to provide a patient with full general anesthesia
for surgery. In addition, volatile anesthetics take effects
very quickly. Most patients anesthetized by these drugs
recover smoothly and quickly. With the aid of modern
equipment, their use is very easy and their concentra-
tions can be accurately monitored. For these reasons,
volatile anesthetics have been popular drugs used in
clinical practice. Modern volatile anesthetics that are
used in the USA include isoflurane (CHF2-O-CHCl-
CF3), sevoflurane (CH2F-O-CH-(CF3)2) and desflurane
(CHF2-O-CHF-CF3). Halothane (CF3-CHBrCl) was used
clinically for more than 40 years and started to be
phased out during 1990s as newer volatile anesthetics
become popular. All of these volatile anesthetics are
halogenated hydrocarbons.
In addition to the anesthetic properties, volatile anes-
thetics have been thought to have neuroprotective
effects for a long time [3,4]. Although the potential for
volatile anesthetics to induce cell injury has been
reported previously, there is a recent surge of concern
on the safety of volatile anesthetics [5-7]. These two
possible effects of volatile anesthetics, neuroprotection
and neurotoxicity, and their implications in clinical
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mechanisms of general anesthesia will be provided
because providing general anesthesia is the main indica-
tion for using volatile anesthetics in humans and ani-
mals and this overview will facilitate the discussion of
volatile anesthetics-induced neuroprotection and
neurotoxicity.
Overview of mechanisms for volatile anesthetics-
induced anesthesia
Although general anesthetics are among the most com-
monly used drugs in clinical practice, the mechanisms
for them to induce anesthesia are not fully understood.
An early theory to explain anesthesia mechanism for
volatile anesthetics is the Meyer-Overton rule [8]. It
states that anesthetic potency increases with lipid solubi-
lity. This theory implies that general anesthetics are dis-
solved in the lipid fraction of brain cells to change the
activity of these cells, which leads to anesthesia. Strong
evidence to support the Meyer-Overton rule is the find-
ing that there is a linear relationship between the solubi-
lity of volatile anesthetics in olive oil and their
anesthetic potency [8]. Although the Meyer-Overton
rule was the dominant theory to explain general
anesthesia for many decades, many findings have ques-
tioned the correctness of this theory. For example, enan-
tiomers of anesthetics have the same lipid solubility but
different anesthetic potencies [9]. There are also many
non-immobilizers that are similar to volatile anesthetics
in chemical structures and lipid solubility but do not
have significant anesthetic properties [10].
A very popular theory developed in the last 3 decades
to explain general anesthesia is the protein hypothesis.
It states that general anesthetics bind and act on specific
proteins to change their functions and cell activity,
which results in anesthesia [11]. Consistent with this
hypothesis, functions/activities of numerous proteins
have been found to be affected by anesthetics. These
proteins include receptors, ion channels and neurotrans-
mitter transporters whose changes in functions can alter
the activity of the brain cells [2,11,12]. Since there are
excitatory and inhibitory neurotransmissions in the cen-
tral nervous system (CNS), a simply view of the protein
hypothesis is that general anesthesia is induced by inhi-
biting the excitatory neurotransmission and/or enhan-
cing the inhibitory neurotransmission. Since glutamate
and g-aminobutyric acid (GABA) are the major excita-
tory and inhibitor neurotransmitters, the role of their
receptors in general anesthesia has been a focus of study
in the last 3 decades [2,11,13].
The most convincing data obtained so far are on
GABA receptors, especially the GABAA receptors.
Multiple studies have shown that general anesthetics
at clinically relevant concentrations enhance GABA
receptor activity. Specific target sites in the receptors
have been extensively studied by using site-directed
mutagenesis [13,14]. It has been shown that S270 in
the a2 subunit of the GABAA receptors is critically
important for the enhancement of GABAA receptor
activity by volatile anesthetics [15]. Mice with muta-
tion on this amino acid residue have a reduced sensi-
tivity to isoflurane [16]. Also, various studies with
other mutations of the GABAA receptors in mice have
suggested the importance of these receptors in anes-
thetic effects [14]. Finally, GABAA receptor antago-
nists have been shown to reverse anesthetic effects
[17].
A few lines of evidence have shown the involvement
of glutamate receptors, especially the N-methyl-D-aspar-
tic acid (NMDA) receptors (a subtype glutamate recep-
tors), in the mechanisms of general anesthesia. General
anesthetics at clinically relevant concentrations can
work as NMDA receptor antagonists [13,18]. Knockout
of a subunit of the NMDA receptors in mice signifi-
cantly reduces the anesthetic potency of nitrous oxide,
an inhalation anesthetic [19]. Finally, blockage of
NMDA receptors has been considered as the major
mechanism for the effects of ketamine [20], an intrave-
nous anesthetic.
Multiple other proteins, such as voltage-gated chan-
nels, background channels and neurotransmitter trans-
porters, may be anesthetic targets [2,12,13,21]. This
implication is mostly based on the evidence that anes-
thetics affect the activity of these proteins. In some
cases, limited in vivo animal data are available to sup-
port their role in anesthesia mechanism. However, addi-
tional evidence is needed to establish this role for most
of these proteins.
Associated with the protein hypothesis, identifying the
mechanisms of general anesthesia at a system level has
been a research focus in recent years. General anesthesia
has been commonly described as “putting patients to
sleep” in a layman term. In fact, sleep and general
anesthesia share many features [22]. For example, the
electroencephalographic patterns of patients who are in
non-rapid eye movement sleep or under general
anesthesia are very similar [22-24]. Their brain func-
tional images are similar, too [22,25,26]. However, there
are significant differences between normal sleep and
general anesthesia. For example, it is easy to wake up a
person from sleep. Consciousness recovery from general
anesthesia can be achieved only after the anesthetics are
eliminated from the brain. In supporting this system-
based and sleep-like view of general anesthesia mechan-
isms, injection of the GABAA receptor agonist muscimol
into the tuberomammillary nucleus, a brain region that
is involved in sleep, but not the surrounding brain struc-
tures, causes hypnosis to rats [17]. This finding suggests
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in specific brain regions.
Volatile anesthetics-induced neuroprotection
Neuroprotection induced by application of volatile
anesthetics during brain ischemia
Animal studies
It was reported in 1963 that patients under cyclopro-
pane anesthesia could tolerate longer temporary carotid
occlusion without evidence of brain ischemia [27], sug-
gesting that cyclopropane, a volatile anesthetic, may
have neuroprotective effects. Numerous animal studies
have been performed since then. Most of them show
that volatile anesthetics are neuroprotective [3,4].
It was realized in 1990s that ischemic cell death is a
dynamic process that can last for at least 2 weeks after
brain ischemia in rodents [28]. Experts in the field
recommend determining the long-term protective effects
in pre-clinical studies [29]. To evaluate the long-term
neuroprotective effects of volatile anesthetics when
applied during brain ischemia, an early study subjected
adult rats to middle cerebral arterial occlusion (MCAO)
for 70 min in the presence or absence of 1.5 minimum
alveolar concentrations (MAC) of isoflurane. One MAC
is defined to be the alveolar concentration at which 50%
subjects will not move in response to painful stimula-
tion. Animals with isoflurane exposure during brain
ischemia had smaller infarct volumes than those without
isoflurane exposure at 2 days, but not at 14 days, after
brain ischemia [30]. This result suggests that neuropro-
tective effects of isoflurane may not be long-lasting.
However, a recent study showed that adult rats had
smaller brain infarct volumes and better neurological
outcomes evaluated at 14 or 28 days after brain ische-
mia if 1.8% isoflurane (~1.4 MACs) was applied during
a 50-min or 80-min MCAO [31]. These findings
strongly suggest that isoflurane provides long-lasting
neuroprotection. One important difference between
these two studies is that the early study permanently
ligated the ipsilateral common carotid artery, which
could cause chronic hypoperfusion to the brain regions
including the previously ischemic brain tissues. The sec-
ond study only temporarily occluded the common caro-
tid artery during MCAO. This difference in creating
MCAO may have resulted in the different conclusions
regarding whether isoflurane-induced neuroprotection is
long-lasting.
Multiple mechanisms have been proposed for the neu-
roprotection induced by volatile anesthetics [3,4]. Vola-
tile anesthetics reduce metabolic rate of the brain. This
effect should prolong the ischemic time that can be tol-
erated by the brain tissues and, therefore, should contri-
bute to the anesthetics-induced neuroprotection.
Volatile anesthetics reduce glutamate neurotoxicity due
to their inhibition on glutamate receptors [32]. Since
glutamate-induced over-excitation and the subsequent
cell injury in the brain are a major mechanism for
ischemic brain injury [33], anesthetics may provide neu-
roprotection through their inhibition of glutamate neu-
rotoxicity. Also, increased intracellular calcium plays a
critical role in ischemic brain injury [33]. Volatile anes-
thetics can regulate intracellular calcium concentrations
[34], which may contribute to their neuroprotective
effects.
Clinical studies
Michenfelder et al. [35] performed a retrospective data
review of 2010 patients who had carotid endarterectomy
with the monitoring of electroencephalography (EEG)
and cerebral blood flow (CBF) from January 1, 1972 to
December 31, 1985. Patients who were under isoflurane
anesthesia had a lower critical CBF than patients under
halothane anesthesia. The critical CBF was defined as
flow below which the majority of patients had ipsilateral
ischemic EEG changes within 3 min of carotid occlu-
sion. Patients under isoflurane anesthesia also had a
lower incidence of EEG evidence of brain ischemia than
patients under halothane anesthesia. Since the critical
CBF (20 ml/100 g brain tissue/min) of patients under
halothane anesthesia is similar to that known to cause
EEG changes of brain ischemia when no anesthetics are
used (22 ml/100 g brain tissue/min) [35,36], these
results suggest that isoflurane has neuroprotective
effects in humans.
In a more recent study [37], 20 patients received des-
flurane as maintenance anesthetic during craniotomy.
Patients were then randomized into two groups during
cerebral arterial occlusion: 10 patients received thiopen-
tal and the other 10 received higher concentrations of
desflurane to achieve EEG burst suppression. Patients in
the desflurane group had better preservation of tissue
oxygen saturation than patients in the thiopental group
in the brain areas that were supplied by the occluded
arteries. However, due to the small sample size, the
study did not provide additional neurological outcome
data.
In addition to these human results, two studies have
used adult monkeys to determine volatile anesthetic
neuroprotection [38,39]. These monkeys were subjected
to a 5-h MCAO in one study and a 6-h MCAO in
another study. However, there was no significant differ-
ence in infarct volumes and neurological functional out-
come among the animals that were anesthetized by
isoflurane, thiopental or nitrous oxide plus fentanyl.
These anesthetics were used to achieve EEG burst sup-
pression during brain ischemia.
Thus, there are very limited data suggesting the neu-
roprotective effects of volatile anesthetics applied during
brain ischemia in humans. Up till now, there is no
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these effects. The existing human and animal studies
suffer from the issue that the effects of one anesthetic
are compared to the effects of another drug or a group
of drugs. Although it is difficult to overcome this diffi-
culty in animal studies because animals are needed to
be anesthetized during the creation of brain ischemia,
this issue can be eliminated in human studies if surgical
patients are not used in the study. However, multiple
other issues in human studies can be difficult to control
and confound the interpretation of the results. For
example, there are differences in ischemic severity and
brain regions among patients. Human studies also have
more variables, such as baseline conditions and co-mor-
bidities of patients. These issues should be considered
when a prospective study is designed to determine the
neuroprotective effects of volatile anesthetics.
Neuroprotection induced by application of volatile
anesthetics before brain ischemia
The concept “ischemic preconditioning” was introduced
into the literature in 1986 [40]. Ischemic precondition-
ing describes a phenomenon in which episode(s) of
short ischemia applied before a prolonged episode of
ischemia reduce cell injury caused by the prolonged
ischemia. This protection has two effective time phases.
The acute phase starts minutes after the preconditioning
stimulus and lasts for a few hours. The delayed phase
starts hours after preconditioning stimulus and can last
for many days [41]. These time windows relate when
the prolonged episode of ischemia occurs for the protec-
tive effects to be present. Subsequently, various stimuli
including volatile anesthetics have been found to induce
a preconditioning effect in many organs [41,42].
We and other investigators have found that volatile
anesthetics induce preconditioning effects in the brain
(volatile anesthetic preconditioning-induced neuropro-
tection) [43-45]. We showed that the acute phase of this
protection is anesthetic concentration-dependent. In
case of isoflurane, this protection was maximized by the
exposure to 2% isoflurane for 20 min [44]. Numerous
studies have shown volatile anesthetic preconditioning-
i n d u c e dp r o t e c t i o ni nt h eb r a i na n ds p i n a lc o r d[ 4 6 ] .
This protection appears to improve long-term neurolo-
gical outcome in neonatal or adult rats [47,48]. Multiple
molecules including signaling molecules, such as free
radicals [49], intracellular Ca
++ [50], calcium/calmodu-
lin-dependent protein kinase II [51], mitogen-activated
protein kinase [43], protein kinase B/Akt [50], hypoxia-
inducible factor-1a [52], and inducible nitric oxide
synthase [45,53], have been implicated in the volatile
anesthetic preconditioning-induced neuroprotection.
Since volatile anesthetic preconditioning-induced neuro-
protection has been reviewed previously [46], detailed
description of this subject is not provided here. How-
ever, up till now, there is no clinical study on this sub-
j e c t ,a l t h o u g ha ni nv i t r os t udy using cell cultures has
shown that isoflurane preconditioning also induces pro-
tection in human neuron-like cells [54].
Neuroprotection induced by application of volatile
anesthetics after brain ischemia
The phrase “ischemic postconditioning” was first used in
the literature in 2003 [55]. It describes the protection
induced by introducing short episodes of ischemia dur-
ing the early phase of reperfusion after a prolonged epi-
sode of ischemia. Since this protection does not require
the prediction on when the detrimental ischemia will
occur, postconditioning-induced protection is consid-
ered to be more applicable in the clinical practice. In
fact, post-treatment/postconditioning has been a com-
mon practice to provide medical care because most
patients seek medical attention only after a disease/
injury has occurred.
We have shown that application of isoflurane at the
onset of reperfusion improves neurological outcome
after a 90-min MCAO [56]. There are so far 6 published
studies showing volatile anesthetic post-treatment-/post-
conditioning-induced neuroprotection [51,56-60]. This
protection requires the application of volatile anesthetics
within 1 h after the onset of reperfusion. Isoflurane,
sevoflurane and desflurane at clinically relevant concen-
trations with the exposure times of 30-60 min have
been shown to induce this protection. This protection
can be induced in primary rat neuronal cultures, human
neuron-like cell cultures, adult rats after transient focal
brain ischemia, neonatal rats after brain hypoxia-ische-
mia injury or mice after an intracerebral hemorrhagic
stroke. Various signaling molecules including glycogen
synthase kinase 3b,A k ta n dm i t o c h o n d r i a lK ATP chan-
nels have been implicated in this neuroprotection. How-
ever, there is no clinical study yet to determine whether
volatile anesthetic can induce a postconditioning effect
in the human CNS.
Volatile anesthetics-induced neurotoxicity
Animal studies
Studies on possible anesthetics-induced neurotoxicity
can be divided into two groups based on their age inter-
ests: anesthetics-induced neurotoxicity in adult and neo-
natal animals.
Volatile anesthetics have been shown to affect the cog-
nitive functions of adult animals. Various effects includ-
ing improvement, impairment and no effects on
cognitive functions have been reported in young adult
animals [61-63]. Exposure of elderly rodents (18 months
or older) to volatile anesthetics often impairs the cogni-
tive functions of these animals [62,64]. Since b-amyloid
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neuroinflammation and neurodegeneration are consid-
ered to be underlying pathology for Alzheimer’sd i s e a s e
(AD) [65,66], the most common form of dementia in
elderly, the potential for volatile anesthetics to induce
these changes has been investigated. Although volatile
anesthetics are shown to increase inflammatory cyto-
kines, Ab and activated caspase 3 in the brains of young
adult animals [61,67], no effects on cytokine production
also have been reported in young adult mice [63]. How-
ever, up till now simultaneous determination of the AD-
like brain changes and cognitive functions have been
performed only in four studies. One study showed that
halothane, but not isoflurane, increased amyloid plaque
load in the brains of transgenic mice modeling for AD.
Neither anesthetics increased active caspase 3 expression
and affected the cognitive functions of these animals
[68]. The second study showed that isoflurane anesthe-
sia did not affect the inflammatory cytokine production
in the brain and the cognitive functions of wild-type
young adult mice [63]. Our study showed that exposure
of young adult rats to 1.3% isoflurane for 2 h caused an
acute and brief increase of interleukin 1b, an inflamma-
tory cytokine, and active caspase 3 as well as a
decreased neuronal density in the brain. This exposure
also impaired the cognitive functions [61]. Similarly, we
showed in another study that anesthesia with 1.3% iso-
flurane for 2 h impaired the cognitive functions of
elderly rats. This impairment was abolished by lidocaine
[69], a local anesthetic with anti-inflammatory property.
Our studies appear to suggest that neuroinflammation
and neurodegeneration play a role in the cognitive
impairment. However, the causal relationship between
these pathological changes and cognitive function
impairments cannot be established yet based on the
available data.
The potential detrimental effects of anesthetics on
developing brains have become a hot topic in recent
years due to various factors including the concerns on
the safety of general anesthesia/anesthetics, the possible
implications of these effects in children and their lives
in future, and the investigators’ efforts to increase the
awareness of these effects in the communities. Although
many studies have shown that volatile anesthetics can
increase active caspase 3 expression and cell death in
neonatal animals [5,70,71], a major concern on these in
vivo studies is that many of these studies did not moni-
tor the animals closely during the anesthetic exposure.
This factor and the long exposure (≥ 6 h) often needed
to see the effects raise the questions whether these in
vivo studies faithfully simulate clinical situations and
whether the neuropathology after the anesthetic expo-
sure is indeed caused by anesthetics or changes
occurred during anesthesia, such as hypoxia, hypocarbia
and hypoglycemia. However, many in vitro studies also
have shown that volatile anesthetics induce cell injury
and death in cell cultures isolated from animals [72,73].
The environment of these cell cultures can be closely
monitored and regulated. In addition, a recent study has
shown that isoflurane induces cell apoptosis in the brain
of neonatal rhesus macaque [74]. The anesthesia care of
these macaques was similar to that of humans. Thus,
the available evidence strongly suggests that a prolonged
volatile anesthetic exposure (≥ 4 h) can cause cell injury
and death in the neonatal brains of animals. However, it
is not clear whether these findings from animals can be
extrapolated to humans because volatile anesthetics at
clinically relevant concentrations did not cause cell
injury of human neuron-like cells or neuronal cell line
in our study [75].
Associated with anesthetics-induced cell injury and
death in neonatal animals, volatile anesthetics also have
been shown to impair the cognitive functions of these
animals [5,70,71]. Nevertheless, there is a lack of evi-
dence for the causal relationship between the cell
injury/death in the brain and the cognitive impairment
in the animals after anesthetic exposure.
Clinical studies
Clinical studies on the potential neurotoxicity of volatile
anesthetics can be classified into three categories: the
contribution of general anesthetic exposure to the devel-
opment of postoperative cognitive decline (POCD) and
AD in adult patients and learning and memory impair-
ment in pediatric patients.
POCD is a fairly well-established clinical entity
[76,77]. About 10% elderly patients have POCD at 3
months after non-cardiac surgery compared with ~4%
patients with cognitive decline in the age-matched, non-
surgery control group during the same period [76,77].
However, it appears that general anesthesia/anesthetics
do not contribute significantly to POCD because
patients under general anesthesia do not have an
increased rate of POCD compared with patients under
regional anesthesia [78,79]. On the other hand, a recent
pilot study indicates that patients under isoflurane
anesthesia may have a higher rate of POCD than
patients under desflurane anesthesia after a lower extre-
mity or abdominal surgery [80].
Many retrospective studies have been performed to
determine whether anesthesia and surgery increase the
risk for AD. Five of them including our study do not
show any association of anesthesia and surgery with AD
[81-85]. Two studies suggest a possible role of anesthe-
sia and surgery in AD development. Among them, the
f i r s ts t u d yf o u n dt h a tp a t i e n t sw h or e c e i v e da n e s t h e s i a
and surgery before the age of 50 years had an earlier
onset of AD than those patients receiving anesthesia
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However, in a population-based case-control study, the
investigators using the same group of AD patients
showed that there was no difference in the rate of
anesthesia and surgery between the AD patient group
and the control group [82]. The second study showing a
possible contribution of anesthesia and surgery to AD
found that patients after coronary arterial bypass graft
had an increased risk of being diagnosed with AD com-
pared to patients after percutaneous transluminal coron-
ary angioplasty [87]. Since coronary arterial bypass graft
is a major surgery under general anesthesia and percuta-
neous transluminal coronary angioplasty is a procedure
often under local anesthesia, these results suggest that
general anesthesia and surgery may play a role in AD
development. However, there was no difference in the
percentage of patients who had coronary arterial bypass
graft between AD patients and a control group in a
population-based case control study [85]. Thus, evidence
to suggest a role of general anesthesia and surgery in the
AD development is very weak, if there is any. There is
essentially no direct evidence on whether volatile anes-
thetics contribute to AD development.
A few retrospective studies have investigated the
effects of general anesthesia and surgery occurred early
in life (at the age of ≤ 4 years) on learning and memory
functions of those children assessed later. No studies
have shown that single exposure to general anesthesia
and surgery causes learning and memory impairment in
children. Two studies showed that exposure to multiple
surgeries under general anesthesia increased the risk of
learning disabilities [88,89]. The other 6 studies includ-
ing two studies on twins did not show a link of general
anesthesia and surgery to the development of learning
disabilities [90-95]. The studies using twins are particu-
larly powerful in this setting because they compared the
learning abilities between the discordant twins (one twin
was exposed and the other was not exposed to general
anesthesia and surgery) [94,95]. This design eliminates
many confounding factors, such as genetic background
and social-economic status difference. Thus, the evi-
dence to indicate a role of general anesthesia and sur-
gery in the learning disabilities is weak. The effects of
volatile anesthetics alone on the development of learn-
ing disabilities in children have not been determined yet.
Prospective
Volatile anesthetics have been used in clinical practice
for near 160 years and are still the most commonly used
anesthetics worldwide. There are at least three very
active research fields regarding volatile anesthetic effects
in the CNS: anesthesia mechanisms, anesthetics-induced
neuroprotection and neurotoxicity. The latter two effects
seem contradictory to each other. Although there is
solid evidence from numerous studies for volatile anes-
thetics-induced neuroprotection in animals, clinical data
to support this effect are relatively weak. Data on vola-
tile anesthetics-induced neurotoxicity in animal studies
are accumulated rapidly. However, there are no human
data for this effect yet. There is no prospective and ran-
domized clinical trial yet to evaluate volatile anesthetics-
induced neuroprotection or neurotoxicity. Such data
may be very difficult or even impossible to get for anes-
thetics-induced neurotoxicity because it is not ethical to
anesthetize a large number of people to determine anes-
thetic neurotoxicity. Although data from surgical
patients may provide some hints on this effect, it is not
possible to separate the anesthetic effects from the
effects of many other factors associated with surgery.
On the other hand, it is possible to design a clinical
study to determine volatile anesthetics-induced neuro-
protection by using non-surgical patients.
Logically, it is not difficult to understand that volatile
anesthetics can have both neuroprotective and neuro-
toxic effects. It is often true that everything in our daily
lives has two sides: the good and bad sides. For example,
an appropriate amount of exercises is good for health.
However, over-exercise is harmful. Volatile anesthetic
preconditioning- and postconditioning-induced neuro-
protection often requires anesthetic exposure for less
than 1 h in animal studies [46]. This length of exposure
has not been found to cause significant cell death. The
shortest exposure for volatile anesthetics to cause brain
cell injury is 2 h in both in vivo and in vitro studies.
Most of them have anesthetic exposure for 4 h or longer
[5,71].
Cell responses may be different when they are exposed
to anesthetics in the presence or absence of insult/stress.
Studies have shown that anesthesia/anesthetics reduce
stress responses of surgical patients [96]. However,
unnecessary inhibition of baseline cell activity by anes-
thetics, as is the case for almost all laboratory studies on
the anesthetics-induced neurotoxicity, may cause imbal-
ance of the cell activity, which ultimately leads to cell
injury. Since virtually almost all currently used anes-
thetics have been shown to cause brain cell injury in the
laboratory studies [5,71], one has to wonder what
anesthesiologists can use to anesthetize the patients and
how reliable those laboratory studies are to simulate
clinical situations. In addition, clinicians have to weigh
the risk and benefit of using general anesthetics for sur-
gical patients. Clearly, general anesthesia is necessary
and beneficial in most of these cases.
Conclusions
Volatile anesthetics are commonly used drugs. The
mechanisms for them to induce anesthesia are not fully
understood. The most popular theory in the field now is
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tein targets to induce anesthesia. Currently, volatile
anesthetics-induced neuroprotection and neurotoxicity
are two hot research topics. These two effects seem con-
tradictory to each other and each is supported by suffi-
cient laboratory studies. However, clinical data to
support the neuroprotective effects are relatively weak.
There are no clinical data yet to suggest volatile anes-
thetics-induced neurotoxicity.
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